



# SAFETY DATA SHEET

Page 1 of 3

## SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

**Product:** 600 ASPHALT PRIMER  
**Manufacturer:** W. R. MEADOWS OF WESTERN CANADA  
**Part Number:** 7100-600  
**Address:** 21 Streambank Avenue  
Sherwood Park, AB T8H 1N1  
**Telephone:** (780) 400-1772  
**Revision Date:** 6/27/2024  
**Product Use:** Surface Primer  
In case of emergency, dial (800) 424-9300 (CHEMTREC)

## SECTION 2: HAZARDS IDENTIFICATION/EXPOSURE LIMITS

HMIS		HAZARD STATEMENTS
Health	1	<b>WARNING!</b>
Flammability	2	Causes skin irritation. <b>(Category 2)</b>
Reactivity	0	Flammable liquid and vapor. <b>(Category 3)</b>
Personal Protection		May be fatal if swallowed and enters airway. <b>(Category 1)</b>
		Harmful if inhaled. <b>(Category 4)</b>
		<b>PRECAUTIONARY STATEMENTS:</b>
		Use only in well-ventilated areas.
		Avoid breathing vapors and direct contact.
		Store in well-ventilated location.
		Wear appropriate personal protective equipment.
		Control vapors in confined spaces utilizing mechanical ventilation.



## SECTION 3: HAZARDOUS COMPONENTS

<u>Chemical Name:</u>	<u>CAS Number</u>	<u>% by Weight</u>	<u>SARA 313</u>	<u>Vapor Pressure (mm Hg@20°C)</u>	<u>LEL (@25°C)</u>
1. Petroleum Asphalt	8052-42-4	60-65	No	N/E	N/E
2. Stoddard Solvent	8052-41-3	35-40	No	0.22 mm Hg	0.6

N/E: Not Established

Under the reporting requirements of Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1966 (SARA) and 40 CFR Part 372, chemicals listed on the 313 List (40 CFR Part 373.65) are identified under the heading "SARA 313."

## SECTION 4: EMERGENCY AND FIRST AID PROCEDURES

**EYE CONTACT:** Flush eyes with water for fifteen (15) minutes. If symptoms persist, seek medical attention.

**SKIN CONTACT:** Wash affected areas with mild soap and water. Remove contaminated shoes/clothing. If symptoms persist, seek medical attention. Do not use petroleum solvents to remove solids.

**INHALATION:** If respiratory symptoms develop, move affected individual from exposure source and into fresh air. If symptoms persist, seek medical attention.

**INGESTION:** Dilute with liquid unless the victim is unconscious or very drowsy. Do not induce vomiting. If vomiting spontaneously occurs, prevent lung aspiration. Seek immediate medical attention.

**MOST IMPORTANT SYMPTOMS/EFFECTS, ACUTE AND CHRONIC:** See Section Eleven for Symptoms/Effects.

## SECTION 5: FIRE AND EXPLOSIVES HAZARDS

**FLASHPOINT:** 42 °C TCC

**EXTINGUISHING MEDIA:** Water fog, foam, dry chemical.

**CHEMICAL/COMBUSTION HAZARDS:** Carbon monoxide, carbon dioxide, oxides/compounds of sulfur/nitrogen & incomplete combustion products.

**PRECAUTIONS/PERSONAL PROTECTIVE EQUIPMENT:** Avoid smoke inhalation. Use appropriate personal protective equipment.

# SAFETY DATA SHEET

**Date of Preparation:** 6/27/24 **Page 2 of 3** **7100-600**

## SECTION 6: ACCIDENTAL RELEASE MEASURES

**SPILL OR LEAK PROCEDURES:** Avoid direct contact. Remove ignition sources. Dike and contain spilled material. Remove source of spill if safe to do so. Apply absorbent and place clean-up material in sealed/marked containers for proper disposal.

## SECTION 7: HANDLING AND STORAGE

**SAFE HANDLING PROCEDURES:** Avoid direct contact. For exterior use only. Avoid sources of ignition.

**SAFE STORAGE:** Keep containers closed when not in use. Keep away from ignition sources.

## SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

<u>Chemical Name:</u>	<u>OSHA</u>				<u>ACGIH</u>			
	<u>PEL</u>	<u>PEL/CEILING</u>	<u>PEL/STEL</u>	<u>SKIN</u>	<u>TWA</u>	<u>TLV/CEILING</u>	<u>TLV/STEL</u>	<u>SKIN</u>
1. Petroleum Asphalt	5 mg/m <sup>3</sup> *	N/E	N/E	No	5 mg/m <sup>3</sup> *	N/E	N/E	N/E
2. Stoddard Solvent	N/E	N/E	N/E	No	400 ppm	N/E	N/E	No
		N/E: Not Established		*: Asphalt Fumes				

**ENGINEERING CONTROLS:** Use with adequate ventilation. Use explosion-proof equipment.

**PERSONAL PROTECTIVE EQUIPMENT:** Safety glasses, chemical-resistant gloves.

## SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

<b>BOILING POINT:</b> N/D	<b>VAPOR DENSITY:</b> >1 (air=1)	<b>% VOLATILE BY VOLUME:</b> N/E
<b>EVAPORATION RATE:</b> <1 (Ether=1)	<b>pH LEVEL:</b> N/E	<b>% VOLATILE BY WEIGHT:</b> 35-40 (approximate)
<b>WEIGHT PER GALLON:</b> N/D	<b>PRODUCT APPEARANCE:</b> Black Semi-Solid	<b>VOC CONTENT:</b> 505 g/L
<b>ODOR:</b> Mild Organic	<b>ODOR THRESHOLD:</b> N/D	<b>MELTING/FREEZING POINT:</b> N/D
<b>FLASH POINT:</b> See Section 5	<b>FLAMMABILITY:</b> See Section 5	<b>UEL/LEL:</b> N/D
<b>VAPOR PRESSURE:</b> N/D	<b>RELATIVE DENSITY:</b> N/D	<b>SOLUBILITY:</b> N/D
<b>PARTITION COEFFICIENT:</b> N/D	<b>AUTOIGNITION TEMPERATURE:</b> N/D	<b>DECOMPOSITION TEMPERATURE:</b> N/D
<b>VISCOSITY:</b> N/D	N/D: Not Determined	N/E: Not Established

## SECTION 10: STABILITY/REACTIVITY

**STABILITY:** Stable.

**HAZARDOUS POLYMERIZATION:** Will not occur.

**CONDITIONS AND MATERIALS TO AVOID:** Oxidizing agents, strong acids, and strong alkalies.

**HAZARDOUS DECOMPOSITION PRODUCTS:** Carbon monoxide, carbon dioxide, oxides/compounds of sulfur/nitrogen and incomplete combustion products.

## SECTION 11: TOXICOLOGICAL INFORMATION

**EYE CONTACT:** Direct contact may cause mild to moderate irritation. Product vapors/mists may also cause irritation.

**SKIN CONTACT:** Direct contact may cause slight skin irritation. Prolonged/repeated contact may result in irritation/dermatitis.

**INHALATION:** Exposure may cause irritation of the nose, throat, respiratory tract, and other mucous membranes. Exposure to excessive vapor concentrations may cause signs of transient central nervous system depression (headache, fatigue, drowsiness, dizziness, loss of coordination).

**INGESTION:** May result in irritation of the gastrointestinal tract. Ingestion of excessive quantities may result in symptoms of transient central nervous system depression as noted above.

**SIGNS AND SYMPTOMS:** Symptoms of eye irritation include tearing, reddening, and swelling. Symptoms of skin irritation include redness and swelling. Gastrointestinal irritation symptoms include nausea, vomiting, and abdominal discomfort. Symptoms of respiratory irritation include runny nose, sore throat, coughing, chest discomfort, shortness of breath, and reduced lung function. Symptoms of transient central nervous system depression include: headache, fatigue, drowsiness, dizziness, and loss of coordination.

**AGGRAVATED MEDICAL CONDITIONS:** Pre-existing skin, eye, and respiratory disorders may be aggravated by exposure to this product.

**OTHER HEALTH EFFECTS:** Some asphalts may possess weak carcinogenic activity. Repeated direct skin contact should be avoided.

Occasional contact with asphalt is not expected to have serious health effects as long as good personal hygiene measures are followed.

## SAFETY DATA SHEET

<b>Date of Preparation:</b> 6/27/24	<b>Page 3 of 3</b>	<b>7100-600</b>
<b>SECTION 12: ECOLOGICAL INFORMATION</b>		
<b>ECOTOXICITY:</b> N/E	<b>DEGRADABILITY:</b> N/E	<b>BIOACCUMULATIVE POTENTIAL:</b> N/E
<b>SOIL MOBILITY:</b> N/E	<b>OTHER ADVERSE EFFECTS:</b> None Recognized	<i>N/E: Not Established</i>
<b>SECTION 13: WASTE DISPOSAL INFORMATION</b>		
<b>WASTE DISPOSAL INFORMATION:</b> Fuel blending at a permitted waste disposal facility. Product is a hazardous waste.		
<b>SECTION 14: TRANSPORTATION INFORMATION</b>		
<b>HAZARDOUS/NON-HAZARDOUS MATERIAL:</b> Not regulated by DOT (Domestic Land Transportation).		
<b>UN NUMBER:</b> None.	<b>HAZARD CLASS:</b> N/A	<b>PACKING GROUP:</b> N/A
<b>UN PROPER SHIPPING NAME:</b> N/A		
<b>ENVIRONMENTAL HAZARDS:</b> None recognized.		
<b>BULK TRANSPORTATION INFORMATION:</b> None.		
<b>SPECIAL PRECAUTIONS:</b> None.	<i>N/A: Not Applicable</i>	
<b>SECTION 15: REGULATORY INFORMATION</b>		
<b>OTHER REGULATORY CONSIDERATIONS:</b> None recognized.		
<b>SECTION 16: OTHER INFORMATION</b>		
<b>PREPARATION DATE:</b>	6/27/2024	
<b>PREPARED BY:</b>	Dave Carey	

---

*The information contained herein is based on the data available to us and is believed to be correct. However, we make no warranty, expressed or implied regarding the accuracy of this data or the results to be obtained from the use thereof. We assume no responsibility for injury from the use of this product described herein.*

---